Abstract
Refractoriness to the pharmacological treatment of cancer is dependent on the expression levels of genes involved in mechanisms of chemoresistance and on the existence of genetic variants that may affect their function. Thus, changes in genes encoding solute carriers may account for considerable inter-individual variability in drug uptake and the lack of sensitivity to the substrates of these transporters. Moreover, changes in proteins involved in drug export can affect their subcellular localization and transport ability and hence may also modify the bioavailability of antitumor agents. Regarding pro-drug activation or drug inactivation, genetic variants are responsible for changes in the activity of drugmetabolizing enzymes, which affect drug clearance and may determine the lack of response to anticancer chemotherapy. The presence of genetic variants may also decrease the sensitivity to pharmacological agents acting through molecular targets or signaling pathways. Recent investigations suggest that changes in genes involved in DNA repair may affect the response to platinum-based drugs. Since most anticancer agents activate cell death pathways, the evasion of apoptosis plays an important role in chemoresistance. Several genetic variants affecting death-receptor pathways, the mitochondrial pathway, downstream caspases and their natural modulators, and the p53 pathway, whose elements are mutated in more than half of tumors, and survival pathways, have been reported. The present review summarizes the available data regarding the role of genetic variants in the different mechanisms of chemoresistance and discusses their potential impact in clinical practice and in the development of tools to predict and overcome chemoresistance.
Keywords: Apoptosis, cancer, drug, metabolism, mutation, pharmacology, refractoriness, transport
Current Cancer Drug Targets
Title:Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Volume: 12 Issue: 4
Author(s): J. J.G. Marin, O. Briz, M. J. Monte, A. G. Blazquez and R. I.R. Macias
Affiliation:
Keywords: Apoptosis, cancer, drug, metabolism, mutation, pharmacology, refractoriness, transport
Abstract: Refractoriness to the pharmacological treatment of cancer is dependent on the expression levels of genes involved in mechanisms of chemoresistance and on the existence of genetic variants that may affect their function. Thus, changes in genes encoding solute carriers may account for considerable inter-individual variability in drug uptake and the lack of sensitivity to the substrates of these transporters. Moreover, changes in proteins involved in drug export can affect their subcellular localization and transport ability and hence may also modify the bioavailability of antitumor agents. Regarding pro-drug activation or drug inactivation, genetic variants are responsible for changes in the activity of drugmetabolizing enzymes, which affect drug clearance and may determine the lack of response to anticancer chemotherapy. The presence of genetic variants may also decrease the sensitivity to pharmacological agents acting through molecular targets or signaling pathways. Recent investigations suggest that changes in genes involved in DNA repair may affect the response to platinum-based drugs. Since most anticancer agents activate cell death pathways, the evasion of apoptosis plays an important role in chemoresistance. Several genetic variants affecting death-receptor pathways, the mitochondrial pathway, downstream caspases and their natural modulators, and the p53 pathway, whose elements are mutated in more than half of tumors, and survival pathways, have been reported. The present review summarizes the available data regarding the role of genetic variants in the different mechanisms of chemoresistance and discusses their potential impact in clinical practice and in the development of tools to predict and overcome chemoresistance.
Export Options
About this article
Cite this article as:
J.G. Marin J., Briz O., J. Monte M., G. Blazquez A. and I.R. Macias R., Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs, Current Cancer Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/156800912800190875
DOI https://dx.doi.org/10.2174/156800912800190875 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design Expression of mTOR/70S6K Signaling Pathway in Melanoma Cancer Cells and the Effects of Dacarbazine and Metformin
Current Cancer Therapy Reviews The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug
Protein & Peptide Letters Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Pharmacogenomics of Arylamine N-acetyltransferase
Current Pharmacogenomics FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Suitable Antibacterial Substances for the Treatment of Urinary Tract Infections
Anti-Infective Agents in Medicinal Chemistry Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy
Current Pharmaceutical Design Fluorescence Detection of MMP-9. I. MMP-9 Selectively Cleaves Lys-Gly-Pro-Arg-Ser-Leu-Ser-Gly-Lys Peptide
Current Pharmaceutical Biotechnology Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued) Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry